Annual Drug Patent Expirations for TAFINLAR
Tafinlar is a drug marketed by Novartis and is included in two NDAs. It is available from one supplier. There are twelve patents protecting this drug.
Drug patent litigation for TAFINLAR.
This drug has one hundred and twenty-three patent family members in forty-four countries.
The generic ingredient in TAFINLAR is dabrafenib mesylate. One supplier is listed for this compound. Additional details are available on the dabrafenib mesylate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
